CancerJUMPNCT05800535
JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
An observational study of Cancer and Sarcopenia, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- Cancer, Sarcopenia
- What is being tested?
- Study of the adverse effects of long-term oncological treatments and Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 10 Feb 2025to 10 Feb 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients who have been treated for cancer and who have completed the post-cancer assessment day
Who may be able to join
- Age : 18 to 74 years
- localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy
- patient who benefited from the post-cancer assessment day-
Who cannot join
- Under 18years
- Over 74 years
- Patient who did not received any chemical treatment
- Patient who do not wish to participate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud
Pierre-Bénite, 69310
Cyrille CONFAVREUX, PR, 4 78 86 12 31 ext. +33, Cyrille.confavreux@chu-lyon.fr
About this study
Official title: Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital).
JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers.
Read more
This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day.
This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received.
Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.
- Conditions
- Cancer, Sarcopenia
- Being tested
- Study of the adverse effects of long-term oncological treatments, Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients
- Keywords
- Post cancer, Chemobrain, Sarcopenia, Medical evaluation
- Medical subject headings
- Neoplasms, Sarcopenia, Chemotherapy-Related Cognitive Impairment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Study of the adverse effects of long-term oncological treatmentsDrug
Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patientsBehavioural
Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
| Study group | Role | What they receive |
|---|---|---|
| JUMP Cohort | This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day. Receives: Drug: Study of the adverse effects of long-term oncological treatments; Behavioral: Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of patients with physical and neurocognitive impairment
Number of patients whose medical assessments show altered physical, cognitive or anxiety/dpression activity compared to the measurement in the general population
Measured: at least 1 year later after chemical treatments
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2023
- Study start10 Feb 2025
- Primary completion10 Feb 2029 (estimated)
- Study completion10 Feb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05800535
- Sponsor's protocol ID
- 813
- Other IDs
- 69HCL23_0177
- Acronym
- JUMP
- Status last verified
- Nov 2025
- First submitted
- 24 Mar 2023
- Last updated
- 21 Nov 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients
- ClinicalTrials.gov ID
- NCT05800535
- Acronym / sponsor ID
- JUMP / 813
- Conditions
- Cancer, Sarcopenia
- Keywords
- Post cancer, Chemobrain, Sarcopenia, Medical evaluation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 10 Feb 2025 (actual)
- Primary completion
- 10 Feb 2029 (estimated)
- Study completion
- 10 Feb 2029 (estimated)
- First posted
- 5 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital).
JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers.
This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day.
This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received.
Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| JUMP Cohort | – | Drug: Study of the adverse effects of long-term oncological treatments, Behavioral: Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patientsThis study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day. |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients who have been treated for cancer and who have completed the post-cancer assessment day
Key inclusion criteria (3 listed)
- Age : 18 to 74 years
- localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy
- patient who benefited from the post-cancer assessment day-
Key exclusion criteria (4 listed)
- Under 18years
- Over 74 years
- Patient who did not received any chemical treatment
- Patient who do not wish to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Study of the adverse effects of long-term oncological treatmentsCognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts | Drug | JUMP Cohort |
| Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patientsCognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts | Behavioural | JUMP Cohort |
Primary outcome
Prevalence of patients with physical and neurocognitive impairment
Time frame: at least 1 year later after chemical treatments
Number of patients whose medical assessments show altered physical, cognitive or anxiety/dpression activity compared to the measurement in the general population
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Sarcopenia, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cyrille CONFAVREUX, MD (+334 78 86 12 31, Cyrille.confavreux@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of patients with physical and neurocognitive impairment (time frame: at least 1 year later after chemical treatments). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.